Steve Bryson, PhD,  science writer—

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Parkinson’s cell therapy bemdaneprocel shortens off time

Adults with Parkinson’s disease treated with the cell therapy bemdaneprocel spent less time in off periods, when symptoms were not adequately controlled despite medication use. That’s according to final published data from the exPDite Phase 1 trial (NCT04802733), which also showed that the cell therapy boosted the time…

Cognitive tasks while walking distinguish MSA, Parkinson’s: Study

Performing cognitive tasks while walking may help distinguish between early Parkinson’s disease and multiple system atrophy (MSA), a neurodegenerative disorder with similar symptoms, a study suggests. MSA patients had more walking impairments alongside higher brain activity during cognitive tasks while walking than Parkinson’s patients, the research shows. “We…

Perceived changes in speech due to Parkinson’s, not aging: Study

Age-related declines in speech processes do not appear to contribute to the voice disturbances perceived by people with Parkinson’s disease, and are more likely due to disease processes themselves, a study reports. “Reduced self-voice perception in [Parkinson’s] is likely due to [Parkinson’s]-specific sensory feedback deficits, rather than age per…

AskBio’s gene therapy AB-1005 granted FDA’s RMAT status

AB-1005, AskBio’s investigational gene therapy for Parkinson’s disease, has been granted regenerative medicine advanced therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA). RMAT designation is intended to speed the development and review of therapies that have shown potential to treat serious or life-threatening conditions. Benefits…

Blood pressure treatment eases Parkinson’s tremor in small trial

Propranolol, a blood pressure medication, significantly eased tremor in people with Parkinson’s disease, either at rest or during induced stress, according to findings in a small, placebo-controlled clinical trial. The treatment also significantly attenuated tremor-related brain activity, as indicated on MRI scans. “In about forty percent of patients, […

Potential diagnostic tool finds protein clumps in living cells

Researchers have developed a chemical tag that can detect and measure protein clumping, which is thought to contribute to neurodegenerative diseases like Parkinson’s, in living cells. The potential diagnostic tool, called TME, readily distinguished living white blood cells derived from Parkinson’s patients over those from healthy individuals, outperforming current…